Beyond tacrine: Recently developed cholinesterase inhibitors for the treatment of Alzheimer's disease

CNS Drugs

Volumn 10, Issue 6, 1998, Pages 447-460

  Unni, Latha K ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; HUPERZINE A; METRIFONATE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL;

EID: 0032407485     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810060-00006     Document Type: Article

References (112)

1. Progress report on Alzheimer's disease. In: US Department of Health and Human Services, National Institutes of Health. National Institute on Aging: NIH Publication No. 97-4014, 1997
2. Feldman H, Gracon S. Alzheimer's disease: symptomatic drugs under development. In: Gauthier S, editor. Clinical diagnosis and management of Alzheimer's disease. London: Martin Dunitz, 1996: 239-59
3. Whitehouse PJ, Voci J. Therapeutic trials in Alzheimer's disease. Curr Opin Neurol 1995; 8 (4): 275-8
4. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 11: 1403-5
5. Whitehouse PJ, Price DL. Struble RG, et al Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-9
6. Francis PT, Palmer AM, Sims NR, et al. Neurochemical studies of early-onset Alzheimer's disease. N Engl J Med 1985; 313: 7-11
7. Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983; 40 (2): 503-9
8. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-90
9. Marx J. Searching for drugs that combat Alzheimer's. Science 1996 Jul 5; 273: 50-3
10. Gottfries CG. Therapy options in Alzheimer's disease. Br J Clin Pharmacol 1994; 48 (6): 327-30
11. Becker RE, Giacobini E. Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition: can acetylcholine levels in the brain be improved in Alzheimer's disease? Drug Dev Res 1988; 14: 235-46
12. Becker RE, Giacobini E. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological and therapeutic aspects. Drug Dev Res 1988; 12: 163-95
13. + current. Eur J Pharmacol 1987; 141: 153-7
14. Drukarch B, Leysen JE, Stoof JC. Further analysis of the neuro-pharmacological profile of 9-amino-1.2.3.4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life Sci 1988; 42: 1011-7
15. Smalheiser NR, Swanson DR. Linking estrogen to Alzheimer's disease: an informatics approach. Neurology 1996 Sep: 47 (3): 809-10
16. Stephenson J. More evidence links NSAID, estrogen use with reduced Alzheimer risk. JAMA 1996 May 8; 275 (18): 1389-90
17. Fowler CJ, Tipton KF, MacKay AVP. Human platelet monoamine oxidase - a useful enzyme in the study of psychiatric disorders? Neuroscience 1982; 7: 1577-94
18. Tariot PN, Sunderland T, Weingartner T. et al. Cognitive effects of 1-deprenyl in Alzheimer's disease. Psychopharmacology 1987; 91: 489-95
19. Tariot PN, Cohen RM, Sunderland T, et al. L-Deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987; 44: 427-33
20. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996 Aug: 47 (2): 425-32
21. MacKenzie IR. Anti-inflammatory drugs in the treatment of Alzheimer's disease. J Rheumatol 1996 May; 23 (5): 806-8
22. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 15 (8): 1105-13
23. Oken RJ. Towards a unifying hypothesis of neurodegenerative diseases and a concomitant rational strategy for their prophylaxis and therapy. Med Hypotheses 1995 Oct; 45 (4): 341-2
24. Becker RE, Giacobini E, editors. Alzheimer's disease: from molecular biology to brain. Boston: Birkhauser, 1996
25. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californical: a prototypic acetylcholine binding protein. Science 1991; 251: 872-9
26. Mesulam MM, Moran A. Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Ann Neurol 1987; 22: 223-8
27. Becker RE, Moriearty PL, Unni LK. The second generation of cholinesterase inhibitors: clinical and pharmacological effects. In: Becker R, Giacobini E. editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser, 1991: 263-96
28. Freeman SE, Dawson RM. Tacrine: a pharmacological review. Prop Neurobiol 1991; 36: 257-77
29. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser, 1991: 314-20
30. Ohnishi A, Mihara M, Kamakura H, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 93; 33: 1086-91
31. Unni LK, Womack C, Hannant M, et al. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Methods Find Exp Clin Pharmacol 1994; 16 (4): 285-9
32. Becker RE, Colliver JA, Markwell SJ, et al. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer's disease. Alz Dis Assoc Disord 1996; 10 (3): 124-31
33. Anand R, Hartman RD, Hayes PE. An overview of the development of ENA 713, a brain selective cholinesterase inhibitor. In: Becker R, Giacobini E, editors. Alzheimer's disease: from molecular biology to therapy Boston: Birkhauser, 1996: 239-43
34. Unni LK, Hutt V, Imbimho BP, et al. Kinetics of cholinesterase inhibition of eptastigmine in man. Eur J Clin Pharmacol 1991; 41: 83-4
35. Auteri A, Mosca A, Lattuada A, et al. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. Eur J Clin Pharmacol 1993; 45: 373-6
36. Fulton B, Benfield P. Galanthamine. Drugs Aging 1996; 9 (1): 60-5
37. Kewitz H, Wilcock G, Davis B. Galanthamine in Alzheimer's disease. In: Giacobini E, Becker R, editors. Alzheimer disease: therapeutic strategies. Boston: Birkhauser, 1994: 140-4
38. Bores GM, Huger FP, Petko W. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetyleholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996; 277: 728-38
39. Fink DM, Bores GM, Effland RC, et al. Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer's disease. J Med Chem 1995; 38: 3645-51
40. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985; 142: 28-33
41. Thal JL. Physostigmine in Alzheimer's disease. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser, 1991: 209-15
42. Davis KL, Mobs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139: 1421-4
43. Masur DM, Blau AD, Thal LJ, et al. Measuring changes in memory and cognitive functioning in Alzheimer's disease with administration of oral physostigmine. In: Giacobini E. Becker R. editors. Current research in alzheimer therapy: cholinesterase inhibitors. New York: Taylor and Francis, 1988: 141-51
44. Thal LJ, Masur DM, Sharpless NS, et al. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 627-36
45. Tariot PN, Schneider I., Contemporary treatment approaches to Alzheimer's disease. Consult Pharm 1996; 11 Suppl. E: 16-24
46. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer's disease: report of an open trial. Drug Dev Res 1990; 19: 425-34
47. Summers WK, Majovski LV, Marsh GM, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia. Alzheimer type. N Engl J Med 1986; 315: 1241-5
48. Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995; 28 (6): 449-57
49. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991; 337: 489-42
50. Jogerst G, Alzheimer's disease: the role of tacrine therapy. Iowa Med 1995; 85 (10): 409-11
51. Soares JC. THA historical aspects, review of pharmacological properties and therapeutic effects. Dementia 1995; 6: 225-34
52. Crimson LM. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994 Jun; 28: 744-51
53. Rogers SL, Friedhoff LT. et al. The efficacy and safety of donepezil in patients with Alzheimer's disease, results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303
54. Bryson HM, Benfield P, Donepezil. Drugs Aging 1997 Mar; 10 (3): 234-9
55. Tariot PN, Schneider L, Porsteinson AP. Treating Alzheimer's disease: pharmacologic options now and in the near future. Postgrad Med Jun 1997; 101 (6): 73-90
56. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994 Apr 6: 271 (13): 992-8
57. Boller F, Orgogozo JM. Tacrine: Alzheimer's disease and the cholinergic theory. A critical review and results of a new therapy. Neurologia 1995 May; 10 (5): 194-5
58. Knapp MJ, Knopman DK, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994 Apr: 271 (13): 985-91
59. Davis KL, Thai LJ, Gamzu ER, et al. Double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992 Oct; 327 (18): 1253-9
60. Aricept (donepezil hydrochloride tablets). Package insert, 1996; Eisai, Teaneck (NJ)
61. Becker RE, Moriearty P, Unni L, et al. Cholinesterase inhibitors as therapy in Alzheimer's disease: benefit to risk considerations in clinical application. In: Becker R. Giacobini E. editors. Alzheimer's disease: from molecular biology to therapy. Boston: Birkhauser, 1996: 257-66
62. Becker Re, Colliver JA, Markwell SJ, et al. Effects of metrifonate on cognitive decline in Alzheimer's disease. Ala Dis Assoc Disord 1998; 12 (1): 54-7
63. Morris JC, Cyrus PA, Orazem J. et al. Metrifonate benefits cognitive, behavioural, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-30
64. Kewitz H, Berzeswski, Rainer M, et al. Galanthamine, a selective nontoxic acetylcholinesterase inhibitor, is significantly superior over placebo in the treatment of SDAT [abstract no. P58-147]. Neuropsychopharmacology 1994; 10 (3S Pt 2): 130S
65. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 1998; 13 (5): 391-411
66. Friedhoff LT, Rogers SL. Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease. Presented at the 49th Annual Meeting of the American Academy of Neurology; 1997 Apr 12-19: Boston
67. Metcalf RL, Fukoto RB, March RB. Toxication of Diptrex and DDVP to the housefly. J Eur Entomol 1959; 52: 44-9
68. Talaat S, Amin N, Massry BE. The treatment of bilharziasis and other intestinal parasites with Diptrex: a preliminary report on a hundred cases. J Egypt Med Assoc 1963; 46: 827-32
69. Reiner E, Krauthacker B, Simeon V, et al. Mechanism of inhibition in vitro of mammalian acetylcholinesterase and cholinesterase in solutions of O,O-dimethyl-2,2,2-trichloro-l-hydroxyethyl phosphonate (trichlorphon). Biochem Pharmacol 1975; 24: 717-22
70. Nordgren I, Bergstrom M, Holmsted B, et al. Transformation and action of metrifonate. Arch Toxicol 1978; 41: 3-41
71. Snellen WM. Therapeutic properties of metrifonate. Acta Pharmacol Toxicol 1981; 49: 114-7
72. Holmstedt BR, Nordgren I. Toxicological limitations to cholinomimetic therapy. In: Becker R, Giacobini E. editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser, 1991: 114-7
73. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998; 50: 1214-21
74. Cummings J, Bieber F, Mas J, et al. Metrifonate in Alzheimer's disease: results of a dose-finding study. In: Iqbal K, Winbald B, Nishimura T, et al., editors. Alzheimer's disease: biology, diagnosis and therapeutics. Chichester: John Wiley and Sons, 1997: 665-9
75. Cutler NR, Jhee SS, Cyrus P, et al. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. Life Sci 1998; 62 (16): 1433-41
76. Lamb HM, Faulds D. Metrifonate. Drugs Aging 1997; 11 (6): 490-6
77. Enz A, Meier D. Spiegel R. Effects of novel acetylcholinesterase inhibitors based on the mechanism of enzyme inhibition. In: Giacobini E, Becker R, editors. Alzheimer disease: therapeutic strategies. Boston: Birkhauser, 1994: 125-30
78. Sramek JJ, Anand R, Wardle TS, et al. Safety/tolerability trial of ENA 713 in patients with probable Alzheimer's disease. Lite Sci 1996; 58 (15): 1201-7
79. Enz A, Floersheim P, Cholinesterase inhibitors: an overview of their mechanisms of action. In: Becker R, Giacobini E, editors. Alzheimer's disease: from molecular biology to therapy. Boston: Birkhauser, 1996: 211-5
80. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998; 9 (1): 69-75
81. Unni LK, Radcliffe J, Latham G, et al. Oral administration of heptylphysostigmine in healthy volunteers; a preliminary study. Methods Find Clin Pharmacol 1994; 16 (5): 373-6
82. Imbimbo PI, Lucchelli PE. A pharmacodynamic strategy to optimize the clinical response to eptastigmine (MF-201). In: Giacobini E, Becker R, editors. Alzheimer disease: therapeutic strategies. Boston: Birkhauser, 1994: 103-7
83. McClellan KJ, Benfield P. Eptastigmine. CNS Drugs 1998; 9 (1): 69-75
84. Imbimbo B. Eptastigmine: a cholinergic approach to the treatment of Alzheimer's disease. In: Becker R, Giacobini E, editors. Alzheimer's disease: from molecular biology to therapy. Boston: Birkhauser, 1996: 223-30
85. Canal N, Imbimbo B. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Clin Trials Ther 1996; 60 (2): 218-27
86. Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610-7
87. Harvey AL. The pharmacology of galanthamine and its analogues. Pharmacol Ther 1995; 68 (1): 113-28
88. Thomsen T, Bickel U, Fischer JP, et al. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 1990; 39: 603-5
89. Liu JS, Zhu YL, Yu CM, et al. The structure of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Can J Chem 1986; 64: 837-9
90. Tang XC, DeSarno P, Sugaya K, et al. Effect of huperzine-A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989; 24: 276-85
91. Xiong ZQ, Tang XC. Effect of huperzine A, a novel acetylcholinsterase inhibitor, on radial maze performance in rats. Pharmacol Biochem Behav 1995; 51: 415-9
92. Qian B, Wang M, Zhou Z, et al. Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol Sin 1995 Sep; 16 (5): 396-8
93. Xia Y, Kozikowski AP. A practical synthesis of the Chinese 'nootropic' agent huperzine-A: a possible lead in the treatment of Alzheimer's disease. J Am Chem Soc 1989; III: 4116-7
94. Cheng YS, Lu CZ, Ying ZL. et al. 128 cases of myasthenia gravis treated with huperzine A. New Drugs Clin Remedies 1986; 5 (4): 197-9
95. Grunwald J, Raveh L, Doctor BP, et al. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci 1994; 54 (14): 991-7
96. Moriearty PL, Womack C, Dick BW, et al. Stability of peripheral hematological parameters after chronic acetylcholinesterase inhibition in man. Am J Hematol 1991; 37: 280-2
97. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996; 5: 109-16
98. Sramek JJ, Block GA, Reines SA, et al. A multi-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 1995; 56 (5): 319-26
99. Tang XC, Xiong ZQ, Qian BC, et al. Cognition improvement by oral huperzine A: a novel acetylcholinesterase inhibitor. In: Giacobini E, Becker R, editors. Alzheimer disease: therapeutic strategies. Boston: Birkhauser. 1994: 113-9
100. Xu SS, Gao ZZ, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition and behavior in Alzheimer's disease. Acta Pharmacol Sin 1995; 16 (5): 391-5
101. Han Y, Tang X. Preclinical and clinical progress with huperzine A: a novel acetylcholinesterase inhibitor. In: Becker R, Giacobini E, editors. Alzheimer's disease: from molecular biology to therapy. Boston: Birkhauser, 1996: 245-50
102. Unni LK, Unni RK, Becker RE. A theoretical model to predict the pharmacodynamics of metrifonate, an experimental drug for Alzheimer's disease. Presented at the IMACS International Symposium on Mathematical Modeling and Scientific Computing: 1992 Dec 17: Bangalore
103. Dal-Bianco P, Maly J, Wober Ch, et al. Galanthamine treatment in Alzheimer's disease. J Neural Transm 1991: 33 Suppl.: 59-63
104. Rainer M, Mucke H, Janoch P, et al. Galanthamine treatment in Alzheimer's disease - the identification of responders [abstract no. P174-12]. Neuropsychopharmacology 1994 May; 10 (3S Pt 2): 215S
105. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996; 47: 166-77
106. The economic impact of tacrine in the treatment of Alzheimer's disease. Clin Ther 1997; 19 (2): 330-45
107. Gracon S, Smith F, Hoover T, et al. Long-term tacrine treatment: effect on nursing home placement and mortality. In: Becker R, Giacobini E, editors. Alzheimer's disease: from molecular biology to therapy. Boston: Birkhauser, 1996: 205-9
108. Lubeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer's disease. Med Interface 1994 Oct; 132-8
109. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med 1990; 322: 1272-6
110. Carlton PL. Brain acetylcholine and habituation. Prog Brain Res 1968; 28: 48-60
111. Russell RW. Effects of 'biochemical lesions' on behavior. Acta Psychol 1958; 14: 281-94
112. Mesulam M-M. Butyrylcholinesterase in Alzheimer's disease. In: Giacobini E, Becker R, editors. Alzheimer disease: therapeutic strategies. Boston: Birkhauser, 1994: 79-83